Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132590 | 1.00 | TDP1 (0.44) | TDP1ATMALDH1A1CYP3A4MAPT | |
| SCHEMBL12066584 | 0.84 | TDP1 (0.52) | TDP1ATMALDH1A1CYP3A4MAPT | |
| SCHEMBL26598264 | 0.83 | ERN1 (0.44) | TDP1ATMALDH1A1CYP3A4MAPT | |
| SCHEMBL631164 | 0.82 | ALDH1A1 (0.63) | TDP1ATMALDH1A1CYP3A4MAPT | |
| SCHEMBL432390 | 0.82 | ALDH1A1 (0.63) | TDP1ALDH1A1CYP3A4MAPTMAPK1 | |
| SCHEMBL25424202 | 0.81 | ALDH1A1 (0.42) | TDP1ATMALDH1A1CYP3A4MAPT | |
| SCHEMBL18496986 | 0.80 | ATM (0.48) | TDP1ATMALDH1A1CYP3A4MAPT | |
| SCHEMBL429810 | 0.80 | ALDH1A1 (0.47) | TDP1ATMALDH1A1CYP3A4MAPT | |
| SCHEMBL7420765 | 0.80 | TDP1 (0.41) | TDP1ATMALDH1A1CYP3A4MAPT | |
| SCHEMBL993946 | 0.80 | CYP1A2 (0.52) | TDP1ATMALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| CN-121586717-A | Heteroaryl compounds, process for their preparation and their use in medicine | 江苏恒瑞医药股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-119923401-A | Novel tetraheterocyclic compound | 伊迪恩斯股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119585261-A | PRMT5 inhibitor, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025012057-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024260464-A1 | PI3K INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| CN-116490508-A | KRAS G12D inhibitors | 北京加科思新药研发有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116283954-A | Hydroxamate compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116323624-A | Quinazoline compound and application thereof | 上海医药集团股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230167074-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | FUJIFILM CORPORATION (JP) | 2023-06-01 | — | — | US | disclosed |
| CN-116056766-A | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | 富士胶片株式会社 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023046135-A1 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022188729-A1 | FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022173678-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-114901656-A | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022105857-A1 | KRAS G12D INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167074-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | DHRS9, DHODH, CBR1 | TDP1 3926/4885ATM 4503/4885ALDH1A1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.